Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 2/20 | 0.42 |
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14729256 | 0.85 | NPC1 (0.43) | NPC1RAB9ACA12CA1CA7 | |
| SCHEMBL2141676 | 0.80 | ALDH1A1 (0.51) | RAB9ACA1SYKPPARAALDH1A1 | |
| SCHEMBL6016839 | 0.80 | SYK (0.57) | SYKALDH1A1 | |
| SCHEMBL3110938 | 0.79 | L3MBTL1 (0.49) | NPC1CA12CA1CA7CA14 | |
| SCHEMBL1160560 | 0.78 | NPC1 (0.55) | NPC1RAB9ACA1ALDH1A1 | |
| SCHEMBL14535782 | 0.78 | SYK (0.52) | NPC1RAB9ACA12CA1CA7 | |
| SCHEMBL19853352 | 0.78 | IDO1 (0.54) | CA12CA1CA7CA14SYK | |
| SCHEMBL16761858 | 0.78 | SYK (0.49) | SYKPPARAALDH1A1 | |
| SCHEMBL716007 | 0.78 | NPC1 (0.56) | NPC1RAB9ACA12CA1CA7 | |
| SCHEMBL394244 | 0.78 | ALDH1A1 (0.56) | NPC1RAB9ACA12CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076728-A1 | NOVEL METHOD OF COMBINED MOLECULAR CLAMPING AND ALLELE SPECIFIC qPCR TECHNOLOGY FOR KRAS G12C MUTATION DETECTION | SUN QING (US) | 2024-03-07 | — | — | US | disclosed |
| US-11845934-B2 | Specific synthetic chimeric xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing CRISPR mediated genome editing efficiency | DiaCarta Inc. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220025453-A1 | XENONUCLEIC ACID-MEDIATED MULTIPLEX QPCR CLAMPING TECHNOLOGY FOR LUNG CANCER MUTATION DETECTION | Sha michael y (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220025437-A1 | NOVEL METHOD OF COMBINED MOLECULAR CLAMPING AND ALLELE SPECIFIC qPCR TECHNOLOGY FOR KRAS G12C MUTATION DETECTION | SUN QING (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220025437-A1 | NOVEL METHOD OF COMBINED MOLECULAR CLAMPING AND ALLELE SPECIFIC qPCR TECHNOLOGY FOR KRAS G12C MUTATION DETECTION | SUN QING (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220025453-A1 | XENONUCLEIC ACID-MEDIATED MULTIPLEX QPCR CLAMPING TECHNOLOGY FOR LUNG CANCER MUTATION DETECTION | Sha michael y (US) | 2022-01-27 | — | — | US | disclosed |
| US-11208689-B2 | DNA mutation detection employing enrichment of mutant polynucleotide sequences and minimally invasive sampling | DIACARTA LTD | 2021-12-28 | — | — | US | disclosed |
| US-11208689-B2 | DNA mutation detection employing enrichment of mutant polynucleotide sequences and minimally invasive sampling | DIACARTA LTD | 2021-12-28 | — | — | US | disclosed |
| US-20190330621-A1 | SPECIFIC SYNTHETIC CHIMERIC XENONUCLEIC ACID GUIDE RNA; s(XNA-gRNA) FOR ENHANCING CRISPR MEDIATED GENOME EDITING EFFICIENCY | POWELL MICHAEL J (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190330621-A1 | SPECIFIC SYNTHETIC CHIMERIC XENONUCLEIC ACID GUIDE RNA; s(XNA-gRNA) FOR ENHANCING CRISPR MEDIATED GENOME EDITING EFFICIENCY | POWELL MICHAEL J (US) | 2019-10-31 | — | — | US | disclosed |
| EP-1299354-B1 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-22 | — | — | EP | disclosed |
| EP-1417219-A4 | LIBRARIES OF CONFORMATIONALLY CONSTRAINED PEPTIDES, CHIRAL AZACROWNS, AND PEPTIDOMIMETICS AND METHODS OF MAKING THE SAME | METAPHORE PHARMACEUTICALS INC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040236519-A1 | Libraries of confomationally constrained peptides, chiral azacrowns, and peptidomimetics and methods of making the same | METAPHORE PHARMACEUTICALS, INC. | 2004-11-25 | — | — | US | disclosed |
| US-6743790-B2 | A UREA OR THIOUREA DERIVATIVES CONTAINING AMIDE GROUP USEFUL AS ANTICOAGULANTS AND ANTIINFLAMMATORY AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| EP-1417219-A2 | LIBRARIES OF CONFORMATIONALLY CONSTRAINED PEPTIDES, CHIRAL AZACROWNS, AND PEPTIDOMIMETICS AND METHODS OF MAKING THE SAME | Metaphore Pharmaceuticals Inc. (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1299354-A2 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | Aventis Pharma Deutschland GmbH (DE) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002100883-A2 | LIBRARIES OF CONFORMATIONALLY CONSTRAINED PEPTIDES, CHIRAL AZACROWNS, AND PEPTIDOMIMETICS AND METHODS OF MAKING THE SAME | METAPHORE PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-20020052417-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-05-02 | — | — | US | disclosed |
| WO-2001094301-A2 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-13 | — | — | WO | disclosed |
| EP-1162194-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | Aventis Pharma Deutschland GmbH (DE) | 2001-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330621-A1 | SPECIFIC SYNTHETIC CHIMERIC XENONUCLEIC ACID GUIDE RNA; s(XNA-gRNA) FOR ENHANCING CRISPR MEDIATED GENOME EDITING EFFICIENCY | XPA, CDA, GDA | NPC1 1064/4885RAB9A 2249/4885CA12 4349/4885 |
| US-11845934-B2 | Specific synthetic chimeric xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing CRISPR mediated genome editing efficiency | XPA, CDA, GDA | NPC1 1064/4885RAB9A 2249/4885CA12 4349/4885 |
| US-20020052417-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | F7, F9, F5 | NPC1 1638/4885RAB9A 1725/4885CA12 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.